Full text is available at the source.
Abstract
The evaluation focuses on tirzepatide's impact on various health metrics in adults with Type 1 diabetes and obesity.
- Tirzepatide may affect body weight in individuals with Type 1 diabetes.
- It is associated with changes in glycaemic control.
- Insulin requirements could be modified with tirzepatide treatment.
- Continuous glucose monitoring metrics may show variations due to the intervention.
- The effect on cardiorenal parameters is also being assessed.
Simplified